Coronavirus disease 2019 (COVID-19) is characterized by severe acute respiratory syndrome coronavirus 2 (SARSCoV-2) needing mechanical ventilation and intensive care unit (ICU) treatment. In addition to lung disease, clinical features of SARS-CoV-2 include myocardial damage and ischemia-related vascular disease, which are associated with a hypercoagulable state (e.g., high D-dimer levels) predisposing to thrombotic-related complications and eventually death.1–3 Serum albumin levels <3.5 g/dL are detectable in SARS-CoV-2 patients and associated with death4 and elevated D-dimer and thrombotic events,5 which is in accordance with previous studies reporting an association between serum albumin <3.5 g/dL and risk of venous and arterial thrombosis.6 Thus, we tested the hypothesis that albumin supplementation could dampen hypercoagulability in SARS-CoV-2 with serum albumin <3.5 g/dL. This is an observational cohort study performed at a large university hospital located in Rome and Chieti (Italy) and devoted to COVID-19 care.
Albumin supplementation dampens hypercoagulability in COVID-19. A preliminary report / Violi, F.; Ceccarelli, G.; Loffredo, L.; Alessandri, F.; Cipollone, F.; D'Ardes, D.; D'Ettorre, G.; Pignatelli, P.; Venditti, M.; Mastroianni, C. M.; Pugliese, F.. - In: THROMBOSIS AND HAEMOSTASIS. - ISSN 0340-6245. - 121:1(2021), pp. 102-105. [10.1055/s-0040-1721486]
Albumin supplementation dampens hypercoagulability in COVID-19. A preliminary report
Violi F.
;Ceccarelli G.;Loffredo L.;Alessandri F.;Cipollone F.;D'Ardes D.;D'Ettorre G.;Pignatelli P.;Mastroianni C. M.;Pugliese F.
2021
Abstract
Coronavirus disease 2019 (COVID-19) is characterized by severe acute respiratory syndrome coronavirus 2 (SARSCoV-2) needing mechanical ventilation and intensive care unit (ICU) treatment. In addition to lung disease, clinical features of SARS-CoV-2 include myocardial damage and ischemia-related vascular disease, which are associated with a hypercoagulable state (e.g., high D-dimer levels) predisposing to thrombotic-related complications and eventually death.1–3 Serum albumin levels <3.5 g/dL are detectable in SARS-CoV-2 patients and associated with death4 and elevated D-dimer and thrombotic events,5 which is in accordance with previous studies reporting an association between serum albumin <3.5 g/dL and risk of venous and arterial thrombosis.6 Thus, we tested the hypothesis that albumin supplementation could dampen hypercoagulability in SARS-CoV-2 with serum albumin <3.5 g/dL. This is an observational cohort study performed at a large university hospital located in Rome and Chieti (Italy) and devoted to COVID-19 care.File | Dimensione | Formato | |
---|---|---|---|
Violi_Albumin-supplementation_2021.pdf
accesso aperto
Tipologia:
Versione editoriale (versione pubblicata con il layout dell'editore)
Licenza:
Tutti i diritti riservati (All rights reserved)
Dimensione
170.88 kB
Formato
Adobe PDF
|
170.88 kB | Adobe PDF |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.